Deloitte is cutting GLP-1 coverage for weight loss and raising health insurance costs for US staff

Deloitte's US workforce are joining the expanding catalog of workers facing additional costly and small generous healthcare benefits.

According to an inner benefits guide seen by Business Insider, from January, the Big Four firm volition no longer shield GLP-1 medication for weight-loss purposes through its medicinal plans.

At the identical time, Deloitte workforce volition additionally visage higher deductibles and out-of-pocket maximums under most health plans, the document said, definition higher expenses the two before and following safety kicks in.

The changes arrive as company America battles a general increase in health coverage expenses for the two workforce and employers.

Deloitte told personnel in the document that the changes "reflect the difficult trade-offs of today's disbursal environment," and that there was a need "for shared duty in a few particular places anywhere it's rotate into untenable for Deloitte to transport the disbursal alone."

GLP-1 medication volition remain covered whenever prescribed for diabetes and another covered medicinal conditions, the document said. For those seeking assistance alongside importance loss, Deloitte is alternatively offering workforce admission to a virtual manner program called eMed that includes coaching and a $125-per-prescription employer contribution.

List prices for average GLP-1s akin semaglutide and tirzepatide are mostly in excess of $1,000, although straightforward acquisition programs specified as LillyDirect and authorities plans akin TrumpRx average the expenses are frequently considerably lower.

TrumpRx, for instance, offers semaglutide injection pens under the Ozempic brand name for between $199 and $499.

A Deloitte spokesman told Business Insider that, akin another ample employers, the resolute has made choose modifications anywhere disbursal growth rates are no longer sustainable. The new assistance for weight-related uses of GLP-1s includes direct-from-manufacturer medication pricing, they said.

"Our financial dedication to our group and their families continues to grow," the spokesman said.

Deloitte is additionally expanding certain healthcare coverage, including improving long-term impairment safety and adding liberated annual eye exams to its company-paid discount imagination program.

The benefits guide seen by Business Insider applies to what Deloitte calls its "Core, Domain, and Enterprise professionals," which includes the bulk of its traditional client-facing accountants, consultants, and specialized specialists. The resolute employs concerning 181,000 group in the US.

Health coverage expenses are rising throughout the board

Deloitte's changes to its safety mirror a broader compression on US director health plans. As healthcare expenses and petition climb, everyone is paying more.

A 2026 health benefits study from KFF established that workers on a family scheme paid an average of $7,471 a twelvemonth in premiums — a 9% addition from 2025. When accounting for director contributions, family scheme premiums totaled $28,303 in 2026, a approximately 5% addition from 2025.

Restricting eligibility for GLP-1s has rotate into a average path for employers looking to curb healthcare spending.

The narcotics were developed to treat diabetes, but have rotate into sought-after treatments for obesity and connected chronic conditions. Aon, an coverage agent and employee-benefits consultancy, established that use of GLP-1s was up 75% in 2025.

The drugs' fast uptake and possible for long-term use have made them a costly force item for insurers and director health plans. Aon established that 39% of employers planned to decrease or restrict GLP-1 safety in 2026.

PwC and Starbucks are among those that have pulled rear their safety for weight-loss purposes this year.

Deloitte has additionally introduced broader advantage changes for a choose collection of staff. In April, Business Insider reported that for personnel in Deloitte's Center endowment example — which mostly includes internal-facing admin roles — parental leave, annual PTO, and IVF backing would be reduced or eliminated as of January 1, 2027.

Deloitte's Americas division was its slowest-growing area globally in the financial twelvemonth ending May 31, 2026, alongside income rising 3.2%, downward from 7.1% growth a twelvemonth earlier.